Omega‐3 fatty acids (from fish oils) for cystic fibrosis

Scolaris Content Display Scolaris Content Display

Ir a:

Analysis 1.1

Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 1 Adverse events.

Analysis 1.2

Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 2 Lung function.

Analysis 1.3

Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 3 Clinical variables.

Analysis 1.4

Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 4 Changes in biochemical markers of essential fatty acid status.

Comparison 1. Omega‐3 fatty acids versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Adverse events Show forest plot	1		Odds Ratio (M‐H, Fixed, 95% CI)	Totals not selected

1.1 Diarrhoea and eructation	1		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Lung function Show forest plot	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

2.1 FEV1 % predicted	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 FVC % predicted	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Clinical variables Show forest plot	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

3.1 Change in body mass index	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Changes in biochemical markers of essential fatty acid status Show forest plot	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

4.1 EPA % content of neutrophil membrane	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 DHA % content of neutrophil membrane	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]

Comparison 1. Omega‐3 fatty acids versus placebo